HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, E. A. Articles by Sundgren, P. C. Search for Related Content PubMed PubMed Citation Articles by Smith, E. A. Articles by Sundgren, P. C. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Developing a Clinical Decision Model: MR Spectroscopy to Differentiate Between Recurrent Tumor and Radiation Change in Patients with New Contrast-Enhancing Lesions

¹ Department of Radiology, University of Michigan Health System, 1500 E Medical Center Dr., Ann Arbor, MI 48109-5030.
² Department of Neurology, University of Michigan Health Systems, Ann Arbor, MI.
³ Department of Radiation Oncology, University of Michigan Health Systems, Ann Arbor, MI.

OBJECTIVE. Differentiation between recurrent neoplasm and postradiation change in patients previously treated for primary brain tumors is often difficult based on imaging features alone. The purpose of this study was to develop a method using alterations in the ratios of standard brain metabolites—choline (Cho), creatine (Cr), and N-acetylaspartate (NAA)—to predict the probability of tumor recurrence in patients previously treated for brain tumors with new contrast-enhancing lesions.

MATERIALS AND METHODS. Thirty-three patients who had undergone treatment for primary brain tumors in whom routine MRI showed new contrast-enhancing lesions were retrospectively studied. The final diagnosis was assigned using histopathology (n = 13) or imaging follow-up (n = 20; range, 2–27 months). Ratios of three metabolites (Cho, Cr, and NAA) were calculated, and the results were correlated with the final diagnosis using a Wilcoxon's rank sum analysis. A logistic regression model was then used to create a prediction model based on the most statistically significant ratio.

RESULTS. Elevations of the metabolic ratios Cho/Cr (p < 0.001) and Cho/NAA (p < 0.001) and a decrease in the ratio NAA/Cr (p = 0.018) were found in patients with recurrent tumor (n = 20) versus those with postradiation change (n = 13). A prediction model using the Cho/NAA ratio yielded a sensitivity of 85%, a specificity of 69.2%, and an area under the receiver operating characteristic curve of 0.92.

CONCLUSION. An elevated Cho/NAA ratio correlated with evidence of tumor recurrence and allowed creation of a prediction rule to aid in lesion classification. The results suggest that MR spectroscopy is a useful tool in assigning patients with nonspecific enhancing lesions to either invasive biopsy or conservative management.

Keywords: brain neoplasms • MR spectroscopy • postradiation changes • postradiation necrosis • recurrent glioma

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P.C. Sundgren MR Spectroscopy in Radiation Injury AJNR Am. J. Neuroradiol., September 1, 2009; 30(8): 1469 - 1476. [Abstract] [Full Text] [PDF]